XML 22 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Mar. 24, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2025    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-42271    
Entity Registrant Name Bicara Therapeutics Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 83-2903745    
Entity Address, Address Line One 116 Huntington Ave    
Entity Address, Address Line Two Suite 703    
Entity Address, City or Town Boston    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02116    
City Area Code 617)    
Local Phone Number 468-4219    
Title of 12(b) Security Common Stock, par value $0.0001    
Trading Symbol BCAX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction Flag false    
Entity Shell Company false    
Entity Public Float     $ 376.7
Entity Common Stock, Shares Outstanding   65,467,187  
Documents Incorporated by Reference
Part III of this Annual Report on Form 10-K incorporates by reference portions of the registrant’s Definitive Proxy Statement for its 2026 Annual Meeting of Shareholders, which the registrant anticipates will be filed with the Securities and Exchange Commission no later than 120 days after the end of its 2025 fiscal year pursuant to Regulation 14A.
    
Entity Central Index Key 0002023658    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Amendment Flag false